Industry Satellite Symposia

NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

Monday, September 16
5:45 PM - 7:45 PM
Location: Hyatt Regency McCormick Place, Regency Ballroom CDE

5:45 p.m. - 6:15 p.m. - Registration and Dinner
6:15 p.m. - 7:45 p.m. - Symposium
Hyatt Regency McCormick Place, Regency Ballroom CDE
Dinner will be provided.

Accreditation: This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CME Credits: The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Target Audience: The activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, and other clinicians involved in the management of patients with lung cancer.

Overview: The standard of care in stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC) has changed for the first time in many years with the approval of immune checkpoint inhibitor therapy for patients who have not progressed following concurrent chemoradiotherapy. However, there are still practical, real-world challenges and questions related to appropriate candidate selection and optimal integration of immunotherapy in this setting. Checkpoint inhibitors are now also being explored in earlier stages of lung cancer, and many clinical trials are assessing various combinatorial or sequential strategies with other treatment modalities. How can radiation oncologists effectively collaborate with medical oncologists, surgeons, and other specialists to ensure that the right patients receive the right treatment at the right time? What needs to be done to further improve outcomes in patients with early-stage lung cancer through rational use of immunotherapy as a component of multi-modal therapy? These and many other important questions will be addressed in this educational event that will merge a MasterClass focused on the latest evidence and key clinical trials with a multi-disciplinary Tumor Board that will examine a series of challenging cases and hone in on practical issues relevant to radiation oncologists managing patients with lung cancer during the era of immuno-oncology.

Learning Objectives:

After participating in the activity, the learners are expected to be better able to:


Assets

NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer



Attendees who have favorited this

  • Behrooz Hakimian
    md
    Cedars-Sinai Medical Center
  • Lesley Hughes
    Physician
    Wellspan Health Oncology
  • Sutthisak Kulpisitthicharoen
    MD
    Lopburi Cancer Hospital

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer